FIELD: medicine.
SUBSTANCE: to induce tumour cell death in an experiment, HCT116, Jurkat, U937 lines tumour cells are simultaneously subjected to a combined treatment with recombinant DR5-B preparation and 0.1 nM of bortezomib. At that, DR5-B used in a concentration at which the half-maximal effective concentration of DR5-B is 0.330.08± ng/ml for HCT116 cell line, 0.060.01± ng/ml for Jurkat cell line, and± 0.090.02 ng/ml for U937 line.
EFFECT: overcoming of tumour cell lines resistance to TRAIL DR5-B in an experiment.
2 cl, 6 dwg, 5 tbl, 3 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD OF PRODUCING HUMAN RECOMBINANT ANTI-TUMOUR PROTEIN DR5-B | 2018 |
|
RU2687435C1 |
| METHOD OF SUPPRESSING GROWTH OF TUMOURS WITH GENETICALLY MODIFIED VERSION OF TRAIL CYTOKINE | 2019 |
|
RU2727059C1 |
| METHOD FOR MAKING MUTANT HUMAN TRAIL PROTEIN | 2009 |
|
RU2405038C1 |
| ANTIBODY SELECTIVE TO APOPTOSIS INDUCING LIGAND RECEPTOR ASSOCIATED WITH TUMOR NECROSIS FACTOR, AND USES THEREOF | 2001 |
|
RU2298013C2 |
| ANTIBODY SELECTIVE TO RECEPTOR APOPTOSIS-INDUCING LIGAND AND ASSOCIATED WITH TUMOR NECROSIS FACTOR AND ITS USING | 2002 |
|
RU2313537C2 |
| COMBINATION OF ANTIBODY HAVING SELECTIVITY IN RELATES TO APOPTOSIS INDUCING LIGAND RECEPTOR ASSOCIATED WITH TUMOR NECROSIS FACTOR AND OTHER THERAPEUTIC AGENTS | 2002 |
|
RU2313368C2 |
| PROTEIN CONSTRUCT BASED ON A RECEPTOR-SPECIFIC MUTANT VARIANT OF THE ANTITUMOR CYTOKINE TRAIL AS A HYBRID PROTEIN WITH A PEPTIDE SPECIFIC FOR INTEGRIN ΑVΒ3 FOR THE TREATMENT OF SOLID TUMORS | 2022 |
|
RU2802488C1 |
| MULTIFUNCTIONAL HYBRID RECOMBINANT PROTEIN MEDICINAL PRODUCTS FOR THE TREATMENT OF TUMOR DISEASES | 2022 |
|
RU2801367C1 |
| METHOD OF SUPPRESSING TUMOUR GROWTH | 2012 |
|
RU2530592C2 |
| HEMOPOIETIC CELL CD34+ AND USE THEREOF | 2005 |
|
RU2390558C2 |
